Document is current
Any future updates will be listed below
-
Authors
Cuevas-Navarro, Antonio https://orcid.org/0000-0001-6208-6944
Pourfarjam, Yasin https://orcid.org/0009-0009-8881-6824
Hu, Feng https://orcid.org/0000-0001-9605-7594
Rodriguez, Diego J. https://orcid.org/0000-0002-0053-8674
Vides, Alberto
Sang, Ben
Fan, Shijie
Goldgur, Yehuda
de Stanchina, Elisa
Lito, Piro https://orcid.org/0000-0003-2196-3503
- License Information
-
More Information
Article History
Received: 23 April 2024
Accepted: 24 October 2024
First Online: 30 October 2024
Competing interests
: P.L. is listed as an inventor on patents filed by MSKCC regarding treatment of KRAS- or BRAF-mutant cancers; reports grants to his institution from Revolution Medicines, Amgen, Mirati and Boehringer Ingelheim; and reports consulting fees or honoraria from Black Diamond Therapeutics, AmMax, OrbiMed, PAQ-Tx, Repare Therapeutics, Boehringer Ingelheim, Menarini Group and Revolution Medicines, as well as membership on the scientific advisory board of Frontier Medicines, Ikena, Biotheryx and PAQ-Tx (consulting fees and equity in each). The other authors declare no competing interests.
